Annual CFF
$1.78 M
+$15.00 K+0.85%
31 December 2023
Summary:
Foghorn Therapeutics annual cash flow from financing activities is currently $1.78 million, with the most recent change of +$15.00 thousand (+0.85%) on 31 December 2023. During the last 3 years, it has fallen by -$215.69 million (-99.18%). FHTX annual CFF is now -99.18% below its all-time high of $217.47 million, reached on 31 December 2020.FHTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$1.05 M
-$102.16 M-98.98%
30 September 2024
Summary:
Foghorn Therapeutics quarterly cash flow from financing activities is currently $1.05 million, with the most recent change of -$102.16 million (-98.98%) on 30 September 2024. Over the past year, it has dropped by -$336.00 thousand (-24.22%). FHTX quarterly CFF is now -99.18% below its all-time high of $128.51 million, reached on 31 December 2020.FHTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$105.61 M
-$336.00 K-0.32%
30 September 2024
Summary:
Foghorn Therapeutics TTM cash flow from financing activities is currently $105.61 million, with the most recent change of -$336.00 thousand (-0.32%) on 30 September 2024. Over the past year, it has increased by +$104.00 million (+6467.79%). FHTX TTM CFF is now -51.44% below its all-time high of $217.47 million, reached on 31 December 2020.FHTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FHTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +0.8% | -24.2% | +6467.8% |
| 3 y3 years | -99.2% | +108.1% | -18.3% |
| 5 y5 years | -96.6% | - | - |
FHTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -99.2% | +0.8% | -99.0% | +6468.8% | -18.3% | >+9999.0% |
| 5 y | 5 years | -99.2% | +0.8% | -99.2% | +6468.8% | -51.4% | >+9999.0% |
| alltime | all time | -99.2% | +0.8% | -99.2% | +6468.8% | -51.4% | >+9999.0% |
Foghorn Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.05 M(-99.0%) | $105.61 M(-0.3%) |
| June 2024 | - | $103.21 M(+8743.7%) | $105.95 M(+3626.6%) |
| Mar 2024 | - | $1.17 M(+527.4%) | $2.84 M(+59.9%) |
| Dec 2023 | $1.78 M(+0.9%) | $186.00 K(-86.6%) | $1.78 M(+10.6%) |
| Sept 2023 | - | $1.39 M(+1246.6%) | $1.61 M(+190.3%) |
| June 2023 | - | $103.00 K(+1.0%) | $554.00 K(-62.6%) |
| Mar 2023 | - | $102.00 K(+537.5%) | $1.48 M(-16.0%) |
| Dec 2022 | $1.76 M | $16.00 K(-95.2%) | $1.76 M(-92.5%) |
| Sept 2022 | - | $333.00 K(-67.7%) | $23.49 M(-0.7%) |
| June 2022 | - | $1.03 M(+168.2%) | $23.66 M(+4.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $384.00 K(-98.2%) | $22.74 M(+1.4%) |
| Dec 2021 | $22.42 M(-89.7%) | $21.74 M(+4205.0%) | $22.42 M(-82.6%) |
| Sept 2021 | - | $505.00 K(+355.0%) | $129.19 M(-23.8%) |
| June 2021 | - | $111.00 K(+79.0%) | $169.44 M(-22.0%) |
| Mar 2021 | - | $62.00 K(-100.0%) | $217.29 M(-0.1%) |
| Dec 2020 | $217.47 M(+807.3%) | $128.51 M(+215.3%) | $217.47 M(+144.5%) |
| Sept 2020 | - | $40.75 M(-15.0%) | $88.96 M(+84.5%) |
| June 2020 | - | $47.96 M(>+9900.0%) | $48.21 M(>+9900.0%) |
| Mar 2020 | - | $247.00 K | $247.00 K |
| Dec 2019 | $23.97 M(-53.7%) | - | - |
| Dec 2018 | $51.77 M | - | - |
FAQ
- What is Foghorn Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Foghorn Therapeutics?
- What is Foghorn Therapeutics annual CFF year-on-year change?
- What is Foghorn Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Foghorn Therapeutics?
- What is Foghorn Therapeutics quarterly CFF year-on-year change?
- What is Foghorn Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Foghorn Therapeutics?
- What is Foghorn Therapeutics TTM CFF year-on-year change?
What is Foghorn Therapeutics annual cash flow from financing activities?
The current annual CFF of FHTX is $1.78 M
What is the all time high annual CFF for Foghorn Therapeutics?
Foghorn Therapeutics all-time high annual cash flow from financing activities is $217.47 M
What is Foghorn Therapeutics annual CFF year-on-year change?
Over the past year, FHTX annual cash flow from financing activities has changed by +$15.00 K (+0.85%)
What is Foghorn Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of FHTX is $1.05 M
What is the all time high quarterly CFF for Foghorn Therapeutics?
Foghorn Therapeutics all-time high quarterly cash flow from financing activities is $128.51 M
What is Foghorn Therapeutics quarterly CFF year-on-year change?
Over the past year, FHTX quarterly cash flow from financing activities has changed by -$336.00 K (-24.22%)
What is Foghorn Therapeutics TTM cash flow from financing activities?
The current TTM CFF of FHTX is $105.61 M
What is the all time high TTM CFF for Foghorn Therapeutics?
Foghorn Therapeutics all-time high TTM cash flow from financing activities is $217.47 M
What is Foghorn Therapeutics TTM CFF year-on-year change?
Over the past year, FHTX TTM cash flow from financing activities has changed by +$104.00 M (+6467.79%)